Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.50 |
| ▸ | GRM5 | P41594 | 9/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | QDPR | P09417 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21404018 | 0.89 | NAMPT (0.53) | NAMPTSOS1GRM1GRM5PDK4 | |
| SCHEMBL6366609 | 0.89 | NAMPT (0.56) | NAMPTSOS1GRM1GRM5PDK4 | |
| SCHEMBL31174297 | 0.89 | NAMPT (0.56) | NAMPTSOS1GRM1GRM5PDK4 | |
| SCHEMBL29566392 | 0.86 | NAMPT (0.54) | NAMPTSOS1GRM1GRM5PDK4 | |
| SCHEMBL24309445 | 0.86 | NAMPT (0.54) | NAMPTSOS1GRM1GRM5PDK4 | |
| SCHEMBL4892751 | 0.85 | NAMPT (0.53) | NAMPTSOS1GRM1GRM5PDK4 | |
| SCHEMBL30796169 | 0.85 | NAMPT (0.53) | NAMPTSOS1GRM1GRM5PDK4 | |
| SCHEMBL27461711 | 0.85 | NAMPT (0.53) | NAMPTSOS1GRM1GRM5PDK4 | |
| SCHEMBL30736760 | 0.85 | NAMPT (0.52) | NAMPTSOS1GRM1GRM5PDK4 | |
| SCHEMBL19703158 | 0.84 | QDPR (0.56) | NAMPTSOS1GRM1GRM5PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2007018998-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | GRM2, GRM1, GRIN2B | NAMPT 3926/4885SOS1 4700/4885GRM1 2/4885 |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | GRM2, GRM1, GRIN2B | NAMPT 3926/4885SOS1 4700/4885GRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.